Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Liver transplantation for hepatitis B].

V Mejzlík1, P Studeník, J Ondrásek

  • 1Centrum kardiovaskulární a transplantacní chirurgie, Brno.

Vnitrni Lekarstvi
|February 19, 2005
PubMed
Summary

Combined lamivudine and anti-HBs globulin therapy significantly improves liver transplant outcomes for patients with chronic hepatitis B (HBV). This approach effectively suppresses viral replication and reduces graft failure, offering a promising treatment strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin therapy and risk of cancer in patients after heart transplantation.

Bratislavske lekarske listy·2021
Same author

[Liver transplant outcomes in Brno].

Vnitrni lekarstvi·2013
Same author

[Development of immunosuppressant treatment after liver transplant].

Vnitrni lekarstvi·2013
Same author

[Interventional radiology options to address certain complications of the orthotopic liver transplant].

Vnitrni lekarstvi·2013
Same author

[Liver transplants in tumours and alcoholic cirrhoses].

Vnitrni lekarstvi·2013
Same author

[Kidney transplantation from donors dying of methanol intoxication].

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2013

Area of Science:

  • Hepatology
  • Transplant Surgery
  • Virology

Background:

  • Liver transplantation outcomes for chronic hepatitis B (HBV) were historically poor due to high graft recurrence and failure rates.
  • Hepatitis B virus (HBV) recurrence in liver grafts is a major challenge in transplantation.
  • Chronic viral hepatitis B (HBV) significantly impacts liver transplant success.

Purpose of the Study:

  • To evaluate the efficacy of a combined lamivudine and hyperimmune anti-HBs globulin therapy in liver transplant recipients with chronic hepatitis B.
  • To assess the impact of this combined immunoprophylactic regimen on HBV recurrence and graft survival.
  • To investigate the safety and tolerability of combined lamivudine and anti-HBs globulin therapy in liver transplant patients.

Main Methods:

Related Experiment Videos

  • Four male patients with HBV-related cirrhosis underwent liver transplantation.
  • Patients received a combined immunoprophylactic regimen of lamivudine and hyperimmune anti-HBs globulin.
  • HBV DNA levels were monitored pre- and post-transplantation; three patients received pre-transplant lamivudine treatment.

    • Main Results:

    • Sustained suppression of HBV replication (HBV DNA negativity) was achieved and maintained in all four patients during 4–17 months of follow-up.
    • No treatment-associated complications or emergence of resistant HBV mutants were observed.
    • The combined therapy demonstrated very good outcomes in liver transplant recipients.

    Conclusions:

    • Combined lamivudine and hyperimmune anti-HBs globulin therapy significantly improves outcomes for liver transplant recipients with chronic hepatitis B.
    • This regimen effectively prevents HBV recurrence and maintains graft function.
    • While effective, the potential for resistant mutant development necessitates exploring newer antivirotics like adefovir or tenofovir.